Study on epidemiology, risk factors and clinical characteristics of triple negative breast cancer in Bangladesh

Fatema Tuz Zohora, Mohammad Fazle Rabbi


Breast cancer is the second most common type of cancer in Bangladesh. Although significant improvement has been made in breast cancer treatment and management, Triple Negative Breast Cancer (TNBC) is still the least known breast cancer subtype in this country. TNBC is well known for its aggressive nature and limited therapeutic options when compared to other breast cancer subtypes. Several population-based studies indicated high prevalence of TNBC in African women in addition to few recent studies indicating a growing number of TNBC patients among Asian population. However, there is a lack of evidence on TNBC patients in Bangladesh due to limited knowledge and awareness. In this paper we review the epidemiology, general risk factors and clinical characteristics of TNBC to find out the correlation between TNBC and other conventional breast cancer subtypes in Bangladesh. Some diagnostic and therapeutic approaches as well as future novel solutions for TNBC are also discussed to understand the pathologic process and treatment strategies of TNBC. Literature review reveals that, there is a lack of TNBC studies in Bangladesh. Therefore, more investigations should be carried out to address the degree of vulnerability of TNBC in breast cancer patients of Bangladesh.


Clinical characteristics, Epidemiology, Novel targets, Triple negative breast cancer, Risk factors

Full Text:



Ossovskaya V, Wang Y, Budoff A, Xu Q, Lituev A, Potapova O, et al. Exploring molecular pathways of triple-negative breast cancer. Genes cancer. 2011 Sep;2(9):870-9.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784-95.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals Oncol. 2011 Jun 27;22(8):1736-47.

Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5(1):5-23.

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clinical cancer research. 2007 Apr 15;13(8):2329-34.

Ghosn M, Hajj C, Kattan J, Farhat F, El Karak F, Nasr F, et al. Triple-negative breast cancer in Lebanon: a case series. The oncologist. 2011 Nov 1;16(11):1552-6.

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J clinical oncology. 2008 Mar 10;26(8):1275-81.

Pogoda K, Niwińska A, Murawska M, Pieńkowski T. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. Med Oncol. 2013;30(1).

Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012;23(suppl 6):vi7-vi12.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International J cancer. 2015 Mar 1;136(5):E359-86.

Moore MA, Shin HR, Curado MP, Sobue T. Establishment of an Asian Cancer Registry Network: problems and perspectives. Asian Pac J Cancer Prev. 2008 Jan 1;9(4):815-32.

Hossain MS, Ferdous S, Karim-Kos HE. Breast cancer in South Asia: A Bangladeshi perspective. Cancer Epidemiol. 2014;38(5):465-70.

Mostafa M, Larsen M, Love R. Estrogen Receptor, Progesterone Receptor, and Her-2/neu Oncogene Expression in Breast Cancers Among Bangladeshi Women. J Bangladesh Coll Phys Surg. 2010;28(3):157-162.

Rahman M, Ahsan A, Begum F, Rahman K. Epidemiology, risk factors and tumor profiles of breast cancer in Bangladeshi underprivileged women. Gulf J Oncolog. 2015;1(17):34-42.

Jack RH, Davies EA, Renshaw C, Tutt A, Grocock MJ, Coupland VH, et al. Differences in breast cancer hormone receptor status in ethnic groups: a London population. European J Cancer. 2013 Feb 1;49(3):696-702.

Yeh J, Chun J, Schwartz S, Wang A, Kern E, Guth AA, et al. Clinical Characteristics in Patients with Triple Negative Breast Cancer. International J Breast Cancer. 2017;2017:21-23.

Kurian AW, Fish K, Shema SJ, Clarke CA. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res. 2010;12(6):R99.

Jana D, Mandal S, Mukhopadhyay M, Mitra D, Mukhopadhyay SK, Sarkar DK. Prognostic significance of HER-2/neu and survival of breast cancer patients attending a specialized breast clinic in Kolkata, Eastern India. Asian Pac J Cancer Prev. 2012;13(8):3851-5.

Ambroise M, Ghosh M, Mallikarjuna VS, Kurian A. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev. 2011;12(3):625-9.

Ghosh J, Gupta S, Desai S, Shet T, Radhakrishnan S, Suryavanshi P, et al. Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. Indian J cancer. 2011 Oct 1;48(4):391.

Sharma M, Sharma JD, Sarma A, Ahmed S, Kataki AC, Saxena R, et al. Triple negative breast cancer in people of North East India: critical insights gained at a regional cancer centre. Asian Pac J Cancer Prev. 2014 Jan 1;15(11):4507-11.

Teoh KH, Looi LM, Sabaratnam S, Cheah PL, Nazarina AR, Mun KS. An analysis of predictive biomarkers in routine histopathological reporting of infiltrating ductal breast carcinoma in a tertiary hospital in Malaysia with a focus on limitations and directions for future development. Malays J Pathol. 2011;33(1):35-42.

Tan GH, Taib NA, Choo WY, Teo SH, Yip CH. Clinical characteristics of triple-negative breast cancer: experience in an Asian developing country. Asian Pac J Cancer Prev. 2009;10(3):395-8.

N Rhodes A, Yip C. Comparison of breast cancer in Indonesia and Malaysia-a clinico-pathological study between Dharmais Cancer Centre Jakarta and University Malaya Medical Centre, Kuala Lumpur. Asian Pacific J Cancer Prevention. 2011;12:2943-6.

Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann surgical oncology. 2013 Oct 1;20(10):3254-8.

Afroz S, Rahman SS, Hossain MM. A Study Survey on Risk Factors Associated with Breast Cancer in Bangladeshi Population. J Cancer Sci Ther. 2017;09(05):463-7.

Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, et al. Association between common risk factors and molecular subtypes in breast cancer patients. The Breast. 2013 Jun 1;22(3):344-50.

Choi Y, Park SK, Ahn KJ, Cho H, Kim TH, Yoon HK, et al. Being overweight or obese increases the risk of progression in triple-negative breast cancer after surgical resection. J Korean Med Sci. 2016 Jun 1;31(6):886-91.

Xing P, Li J, Jin F. A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China. Med Oncol. 2010;27(3):926-31.

Islami F, Liu Y, Jemal A, Zhou J, Weiderpass E, Colditz G, et al. Breastfeeding and breast cancer risk by receptor status-a systematic review and meta-analysis. Annals Oncol. 2015;26(12):2398-407.

Iqbal J, Ferdousy T, Dipi R, Salim R, Wu W, Narod SA, Kotsopoulos J, et al. Risk Factors for Premenopausal Breast Cancer in Bangladesh. Int J Breast Cancer. 2015;2015:1-7.

Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol. 2009;220(2):n/a-n/a.

Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, et al. Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes. Clin Cancer Res. 2009;15(7):2302-2310.

Noman AS, Uddin M, Rahman MZ, Nayeem MJ, Alam SS, Khatun Z, et al. Overexpression of sonic hedgehog in the triple negative breast cancer: clinicopathological characteristics of high burden breast cancer patients from Bangladesh. Sci Rep. 2016;6:18830.

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-67.

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429-34.

Pervin MM, Nath HD, Bahar MM. Study on clinical presentation of breast carcinoma of 50 cases. Chattagram Maa-O-Shishu Hospital Medical College J. 2014;13(2):8-11.

Aebi S, Davidson T, Gruber G, Cardoso F. Primary breast cancer: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(SUPPL. 6):12-24.

Dogan BE, Turnbull LW. Imaging of triple-negative breast cancer. Ann Oncol. 2012;23(SUPPL. 6).

Chen ZY, Wang YX, Lin Y, Zhang JS, Yang F, Zhou QL, et al. Advance of molecular imaging technology and targeted imaging agent in imaging and therapy. BioMed research international. 2014;2014.

Oakman C, Viale G, Di Leo A. Management of triple negative breast cancer. The Breast. 2010;19(5):312-21.

Crown J, O’Shaughnessy J, Gullo G. Emerging targeted therapies in triple-negative breast cancer. Ann Oncol. 2012;23(suppl 6):vi56-vi65.

Engebraaten O, Vollan HKM, Børresen-Dale AL. Triple-negative breast cancer and the need for new therapeutic targets. Am J Pathol. 2013;183(4):1064-74.

Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol. 2014 Sep 18;25(10):1871-88.

Cigler T, Jain T. Eribulin mesylate in the treatment of metastatic breast cancer. Biol Targets Ther. 2012;6:21.

Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007 Nov 20;25(33):5210-7.

von Minckwitz G, Martin M. Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann Oncol. 2012;23(suppl 6):vi35-vi39.

Clark O, Botrel TEA, Paladini L, Ferreira MBA. Targeted therapy in triple-negative metastatic breast cancer: A systematic review and meta-analysis. Core Evid. 2014;9:1-11.

Story HL, Love RR, Salim R, Roberto AJ, Krieger JL, Ginsburg OM. Improving outcomes from breast cancer in a low-income country: lessons from Bangladesh. Int J Breast Cancer. 2012;2012:1-9.